Informations

Editor’s Note: Breast cancer remains the leading cause of cancer-related deaths among women worldwide, with hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer being the most common molecular subtype. In recent years, targeted therapies, antibody-drug conjugates (ADCs), and selective estrogen receptor degraders (SERDs) have propelled this subtype into the era of precision medicine. Looking back at 2024,…

In 2024, significant progress was made in the field of pediatric acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), bringing new insights and advancements to clinical practice. These studies covered innovations in treatment approaches, evaluations of drug efficacy, and a deeper understanding of the biological characteristics of these diseases. These findings are crucial for…

In 2024, the field of chronic myeloid leukemia (CML) witnessed significant breakthroughs in research and clinical advancements. From the development of novel therapeutic agents to the optimization of treatment strategies, from studies on treatment discontinuation to deeper explorations into disease mechanisms, these findings have expanded treatment options and brought new hope to patients. As we…

In recent years, the field of hematologic malignancies has witnessed remarkable breakthroughs, with Chinese researchers making increasingly significant contributions, particularly in cellular therapy. Their work has played a crucial role in advancing both scientific progress and clinical practice. As we step into the new year, Hematology Frontier has invited Dr. Huilai Zhang from Tianjin Medical…